These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 39171578)

  • 1. Histopathologic, genomic, transcriptomic, and functional characteristics of eight melanocytic tumors with BRAF fusions showing stronger MAPK pathway activation compared to BRAF V600E tumors.
    Li A; Warren SJ; Umphress BA; Alomari AK
    J Cutan Pathol; 2024 Nov; 51(11):899-910. PubMed ID: 39171578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spitz melanoma is a distinct subset of spitzoid melanoma.
    Raghavan SS; Peternel S; Mully TW; North JP; Pincus LB; LeBoit PE; McCalmont TH; Bastian BC; Yeh I
    Mod Pathol; 2020 Jun; 33(6):1122-1134. PubMed ID: 31900433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MAP2K1-mutated melanocytic tumors have reproducible histopathologic features and share similarities with melanocytic tumors with BRAF V600E mutations.
    Alomari AK; Harms PW; Andea AA; Warren SJ
    J Cutan Pathol; 2023 Dec; 50(12):1083-1093. PubMed ID: 37565534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition.
    Hutchinson KE; Lipson D; Stephens PJ; Otto G; Lehmann BD; Lyle PL; Vnencak-Jones CL; Ross JS; Pietenpol JA; Sosman JA; Puzanov I; Miller VA; Pao W
    Clin Cancer Res; 2013 Dec; 19(24):6696-702. PubMed ID: 24345920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition.
    Kim HS; Jung M; Kang HN; Kim H; Park CW; Kim SM; Shin SJ; Kim SH; Kim SG; Kim EK; Yun MR; Zheng Z; Chung KY; Greenbowe J; Ali SM; Kim TM; Cho BC
    Oncogene; 2017 Jun; 36(23):3334-3345. PubMed ID: 28092667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy.
    Botton T; Yeh I; Nelson T; Vemula SS; Sparatta A; Garrido MC; Allegra M; Rocchi S; Bahadoran P; McCalmont TH; LeBoit PE; Burton EA; Bollag G; Ballotti R; Bastian BC
    Pigment Cell Melanoma Res; 2013 Nov; 26(6):845-51. PubMed ID: 23890088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct MAPK and PI3K pathway mutations in different melanoma types in Taiwanese individuals.
    Gao HW; Tsai WC; Perng CL; Wang WM; Chiang CP
    Eur J Dermatol; 2018 Aug; 28(4):509-518. PubMed ID: 30325319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In melanocytic lesions the fraction of BRAF V600E alleles is associated with sun exposure but unrelated to ERK phosphorylation.
    Venesio T; Chiorino G; Balsamo A; Zaccagna A; Petti C; Scatolini M; Pisacane A; Sarotto I; Picciotto F; Risio M
    Mod Pathol; 2008 Jun; 21(6):716-26. PubMed ID: 18408659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of gene fusions in melanocytic neoplasms.
    Quan VL; Panah E; Zhang B; Shi K; Mohan LS; Gerami P
    J Cutan Pathol; 2019 Nov; 46(11):878-887. PubMed ID: 31152596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KIT Suppresses BRAF
    Neiswender JV; Kortum RL; Bourque C; Kasheta M; Zon LI; Morrison DK; Ceol CJ
    Cancer Res; 2017 Nov; 77(21):5820-5830. PubMed ID: 28947418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unclassified sclerosing malignant melanomas with AKAP9-BRAF gene fusion: a report of two cases and review of BRAF fusions in melanocytic tumors.
    Perron E; Pissaloux D; Neub A; Hohl D; Tartar MD; Mortier L; Alberti L; de la Fouchardiere A
    Virchows Arch; 2018 Mar; 472(3):469-476. PubMed ID: 29464327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spectrum and Frequency of BRAF Mutations in Skin Melanomas in the Dalmatian Region of Croatia.
    Bezić J; Tomić I; Pavić M
    Acta Dermatovenerol Croat; 2024 Mar; 32(1):75-76. PubMed ID: 38946192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The distribution of BRAF gene fusions in solid tumors and response to targeted therapy.
    Ross JS; Wang K; Chmielecki J; Gay L; Johnson A; Chudnovsky J; Yelensky R; Lipson D; Ali SM; Elvin JA; Vergilio JA; Roels S; Miller VA; Nakamura BN; Gray A; Wong MK; Stephens PJ
    Int J Cancer; 2016 Feb; 138(4):881-90. PubMed ID: 26314551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving classification of melanocytic nevi: Association of BRAF V600E expression with distinct histomorphologic features.
    Kiuru M; Tartar DM; Qi L; Chen D; Yu L; Konia T; McPherson JD; Murphy WJ; Fung MA
    J Am Acad Dermatol; 2018 Aug; 79(2):221-229. PubMed ID: 29653212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melanocytic naevi with globular and reticular dermoscopic patterns display distinct BRAF V600E expression profiles and histopathological patterns.
    Marchetti MA; Kiuru MH; Busam KJ; Marghoob AA; Scope A; Dusza SW; Cordova MA; Fonseca M; Wu X; Halpern AC
    Br J Dermatol; 2014 Nov; 171(5):1060-5. PubMed ID: 25039578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spectrum of Melanocytic Tumors Harboring BRAF Gene Fusions: 58 Cases With Histomorphologic and Genetic Correlations.
    Roy SF; Milante R; Pissaloux D; Tirode F; Bastian BC; Fouchardière A; Yeh I
    Mod Pathol; 2023 Jun; 36(6):100149. PubMed ID: 36841436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor Activity of BRAF Inhibitor and IFNα Combination in BRAF-Mutant Melanoma.
    Sabbatino F; Wang Y; Scognamiglio G; Favoino E; Feldman SA; Villani V; Flaherty KT; Nota S; Giannarelli D; Simeone E; Anniciello AM; Palmieri G; Pepe S; Botti G; Ascierto PA; Ferrone CR; Ferrone S
    J Natl Cancer Inst; 2016 Jul; 108(7):. PubMed ID: 26851802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRAF inhibitor therapy-associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression.
    Mudaliar K; Tetzlaff MT; Duvic M; Ciurea A; Hymes S; Milton DR; Tsai KY; Prieto VG; Torres-Cabala CA; Curry JL
    Hum Pathol; 2016 Apr; 50():79-89. PubMed ID: 26997441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Comparison of Morphologic and Molecular Features of BRAF, ALK, and NTRK1 Fusion Spitzoid Neoplasms.
    Amin SM; Haugh AM; Lee CY; Zhang B; Bubley JA; Merkel EA; Verzì AE; Gerami P
    Am J Surg Pathol; 2017 Apr; 41(4):491-498. PubMed ID: 27776007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of the mitogen-activated protein kinase pathway in malignant melanoma can occur independently of the BRAF T1799A mutation.
    Yazdi AS; Ghoreschi K; Sander CA; Röcken M
    Eur J Dermatol; 2010; 20(5):575-9. PubMed ID: 20605766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.